Log in

NASDAQ:ZNTLPassage Bio Stock Price, Forecast & News

-2.32 (-4.57 %)
(As of 06/5/2020 04:00 PM ET)
Today's Range
Now: $48.49
50-Day Range
MA: $36.00
52-Week Range
Now: $48.49
Volume165,500 shs
Average Volume198,960 shs
Market Capitalization$1.74 billion
P/E RatioN/A
Dividend YieldN/A
Zentalis Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of breast cancer. The company is also developing ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor that is in Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals, LLC was founded in 2014 and is based in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.81 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ZNTL



Sales & Book Value

Annual SalesN/A



Market Cap$1.74 billion
Next Earnings Date8/21/2020 (Estimated)
OptionableNot Optionable

Receive ZNTL News and Ratings via Email

Sign-up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter.

Passage Bio (NASDAQ:ZNTL) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Passage Bio?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Passage Bio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Passage Bio.

When is Passage Bio's next earnings date?

Passage Bio is scheduled to release its next quarterly earnings announcement on Friday, August 21st 2020. View our earnings forecast for Passage Bio.

How were Passage Bio's earnings last quarter?

Passage Bio (NASDAQ:ZNTL) posted its earnings results on Friday, May, 15th. The company reported ($2.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by $2.18. View Passage Bio's earnings history.

What price target have analysts set for ZNTL?

4 analysts have issued 12 month price objectives for Passage Bio's shares. Their forecasts range from $41.00 to $45.00. On average, they anticipate Passage Bio's stock price to reach $44.00 in the next twelve months. This suggests that the stock has a possible downside of 9.3%. View analysts' price targets for Passage Bio.

Has Passage Bio been receiving favorable news coverage?

Media stories about ZNTL stock have been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Passage Bio earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutPassage Bio.

Who are some of Passage Bio's key competitors?

What other stocks do shareholders of Passage Bio own?

Who are Passage Bio's key executives?

Passage Bio's management team includes the following people:
  • Dr. Anthony Y. Sun M.D., Chairman & Chief Exec. Officer (Age 48)
  • Mr. Kevin D. Bunker Ph.D., Co-Founder & Chief Operating Officer
  • Ms. Melissa B. Epperly, Chief Financial Officer
  • Ms. Kimberley Overs, VP & Gen. Counsel
  • Lawrence Cripe, Director of Corp. Devel.

When did Passage Bio IPO?

(ZNTL) raised $131 million in an initial public offering (IPO) on Friday, April 3rd 2020. The company issued 7,700,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO.

What is Passage Bio's stock symbol?

Passage Bio trades on the NASDAQ under the ticker symbol "ZNTL."

When did the company's quiet period expire?

Passage Bio's quiet period expired on Wednesday, May 13th. Passage Bio had issued 9,180,000 shares in its initial public offering on April 3rd. The total size of the offering was $165,240,000 based on an initial share price of $18.00. During the company's quiet period, insiders and any underwriters involved in the IPO were prevented from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Passage Bio?

Shares of ZNTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Passage Bio's stock price today?

One share of ZNTL stock can currently be purchased for approximately $48.49.

How big of a company is Passage Bio?

Passage Bio has a market capitalization of $1.74 billion.

What is Passage Bio's official website?

The official website for Passage Bio is www.zentalis.com.

How can I contact Passage Bio?

Passage Bio's mailing address is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. The company can be reached via phone at 212-433-3791 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.